Humacyte to Announce 2026 First Quarter Financial Results and Provide Business Update
Humacyte, Inc. will release its financial results for the first quarter of 2026 on May 13, 2026, and will hold a webcast to provide a corporate and financial update. The company is focused on developing bioengineered human tissues and has received FDA approvals for its products related to vascular trauma and hemodialysis.
DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.